lncRNA RHPN1-AS1 Promotes Ovarian Cancer Growth and Invasiveness Through Inhibiting miR-1299.
RHPN1-AS1
invasion
miR-1299
ovarian cancer
proliferation
Journal
OncoTargets and therapy
ISSN: 1178-6930
Titre abrégé: Onco Targets Ther
Pays: New Zealand
ID NLM: 101514322
Informations de publication
Date de publication:
2020
2020
Historique:
received:
02
02
2020
accepted:
01
05
2020
entrez:
2
7
2020
pubmed:
2
7
2020
medline:
2
7
2020
Statut:
epublish
Résumé
Ovarian cancer (OC) is a big threat for public health. However, the molecular mechanism underlying OC development and progression remains unclear. Although the importance of lncRNA in cancer has been proven, how lncRNA is involved in OC is waiting for further investigation. qRT-PCR was performed to test expression level. CCK8 and colony formation were conducted to analyze proliferation. Transwell was conducted to measure migration and invasion. Luciferase reporter assay and pulldown assay were utilized to validate RNA interaction. lncRNA RHPN1-AS1 was highly expressed in OC tissues. RHPN1-AS1 was positively correlated with OC progression and its high expression indicated a low survival rate. Moreover, knockdown of RHPN1-AS1 significantly inhibited the proliferation, migration and invasion of OC cells, and bioinformatics analysis identified that miR-1299 was sponged by RHPN1-AS1 in OC cells. Knockdown of RHPN1-AS1 markedly promoted miR-1299 expression. Of note, inhibition of miR-1299 reversed the roles of RHPN1-AS1 silencing on suppressing proliferation, migration and invasion. Our study demonstrates that RHPN1-AS1 promotes OC progression via sponging miR-1299, suggesting RHPN1-AS1 may be a novel therapeutic target.
Sections du résumé
BACKGROUND
BACKGROUND
Ovarian cancer (OC) is a big threat for public health. However, the molecular mechanism underlying OC development and progression remains unclear. Although the importance of lncRNA in cancer has been proven, how lncRNA is involved in OC is waiting for further investigation.
MATERIALS AND METHODS
METHODS
qRT-PCR was performed to test expression level. CCK8 and colony formation were conducted to analyze proliferation. Transwell was conducted to measure migration and invasion. Luciferase reporter assay and pulldown assay were utilized to validate RNA interaction.
RESULTS
RESULTS
lncRNA RHPN1-AS1 was highly expressed in OC tissues. RHPN1-AS1 was positively correlated with OC progression and its high expression indicated a low survival rate. Moreover, knockdown of RHPN1-AS1 significantly inhibited the proliferation, migration and invasion of OC cells, and bioinformatics analysis identified that miR-1299 was sponged by RHPN1-AS1 in OC cells. Knockdown of RHPN1-AS1 markedly promoted miR-1299 expression. Of note, inhibition of miR-1299 reversed the roles of RHPN1-AS1 silencing on suppressing proliferation, migration and invasion.
CONCLUSION
CONCLUSIONS
Our study demonstrates that RHPN1-AS1 promotes OC progression via sponging miR-1299, suggesting RHPN1-AS1 may be a novel therapeutic target.
Identifiants
pubmed: 32606751
doi: 10.2147/OTT.S248050
pii: 248050
pmc: PMC7293985
doi:
Types de publication
Journal Article
Langues
eng
Pagination
5337-5344Informations de copyright
© 2020 Zhao et al.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest in this work.
Références
Trends Cancer. 2015 Oct 1;1(2):93-109
pubmed: 26693181
J Cell Physiol. 2020 Feb;235(2):1141-1154
pubmed: 31347170
J Cell Biochem. 2019 Aug;120(8):12684-12693
pubmed: 30993801
Biomed Pharmacother. 2016 Oct;83:792-797
pubmed: 27490780
Oncol Rep. 2017 Jun;37(6):3227-3234
pubmed: 28498395
Cell Cycle. 2018;17(14):1772-1783
pubmed: 30010468
Trends Genet. 2018 Oct;34(10):736-745
pubmed: 30017312
J Exp Clin Cancer Res. 2019 Aug 7;38(1):345
pubmed: 31391118
Nat Commun. 2018 Oct 17;9(1):4319
pubmed: 30333487
Eur Rev Med Pharmacol Sci. 2019 Jan;23(2):530-538
pubmed: 30720160
Clin Cancer Res. 2018 Dec 15;24(24):6536-6547
pubmed: 30108103
Theranostics. 2018 Jan 1;8(4):874-877
pubmed: 29463987
Onco Targets Ther. 2019 Jul 11;12:5615-5625
pubmed: 31371999
J Cell Physiol. 2019 Dec;234(12):23421-23436
pubmed: 31222748
Lancet Oncol. 2015 Jan;16(1):87-97
pubmed: 25481791
Int J Mol Sci. 2017 Jan 23;18(1):
pubmed: 28124977
Aging (Albany NY). 2019 Apr 4;11(7):1907-1917
pubmed: 30946694
Open Biochem J. 2018 Feb 28;12:16-28
pubmed: 29576811
Oncogene. 2017 Oct 12;36(41):5661-5667
pubmed: 28604750
Nat Immunol. 2017 May;18(5):499-508
pubmed: 28319097
Nat Commun. 2018 Sep 25;9(1):3917
pubmed: 30254278
Am J Transl Res. 2019 Jun 15;11(6):3505-3517
pubmed: 31312362
J Exp Clin Cancer Res. 2019 Aug 7;38(1):344
pubmed: 31391063
Onco Targets Ther. 2019 Jun 07;12:4469-4480
pubmed: 31239715